GRML (Greenland Mines) Short-Term Debt: $0.30 Mil (As of Mar. 2026)


GRML Greenland Mines Ltd GRML
12 GF Score
Price $0.25
! 1 Warning Sign
View Full Analysis

What is Greenland Mines Short-Term Debt?

Greenland Mines GRML +0.33% 12 Short-Term Debt is $0.30 Mil as of Mar. 2026. GuruFocus rates GRML with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Greenland Mines's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.30 Mil.

Greenland Mines's quarterly Short-Term Debt stayed the same from . 20 ($0.00 Mil) to Mar. 2025 ($0.00 Mil) but then increased from Mar. 2025 ($0.00 Mil) to Mar. 2026 ($0.30 Mil).

Greenland Mines Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Greenland Mines Short-Term Debt Related Terms

Greenland Mines Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Greenland Mines's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenland Mines Short-Term Debt Chart

Greenland Mines Annual Data
Trend
Short-Term Debt

Greenland Mines Semi-Annual Data
Mar25 Mar26
Short-Term Debt 0.00 0.30
GRML
12GF Score
Greenland Mines Ltd GRML
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.30 Mil mean?
Greenland Mines (GRML) has a Short-Term Debt of $0.30 Mil as of Mar. 2026.
Is Greenland Mines' Short-Term Debt too high?
Greenland Mines' current Short-Term Debt is $0.30 Mil. Overall, Greenland Mines has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Greenland Mines' Short-Term Debt compare to SRGZ and RITE?
Greenland Mines' Short-Term Debt of $0.30 Mil can be compared against companies in the Metals & Mining industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Metals & Mining company?
A good Short-Term Debt depends on the Metals & Mining industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Greenland Mines's current Short-Term Debt is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenland Mines stock overvalued right now?
Greenland Mines (GRML) has a current Short-Term Debt of $0.30 Mil. The current Short-Term Debt is $0.30 Mil. Greenland Mines' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Greenland Mines (GRML), the current Short-Term Debt is $0.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenland Mines Business Description

Address 1300 South Boulevard, Unit D, Charlotte, NC, USA, 28203
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
12GF Score

Get the complete analysis for GRML

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price